ArticleCureus2025
Cotyledonoid Dissecting Leiomyoma: A Rare Case With Rapid Regrowth After Fertility-Sparing Surgery and Hormonal Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cotyledonoid dissecting leiomyoma (CDL) is a rare benign variant of uterine leiomyoma. Its multinodular, placental-like morphology often mimics malignant tumors, leading to overtreatment. We report a case of a 34-year-old nulliparous Japanese woman who presented with abdominal distension and urinary frequency, and was subsequently diagnosed with CDL. MRI revealed a 30 cm heterogeneous uterine mass. She desired to preserve fertility, so myomectomy was planned. However, because of the tumor's characteristics, complete resection was difficult and partial resection of the tumor was performed due to intraoperative bladder injury, leaving an 8 cm residual tumor. Histopathology confirmed CDL. Despite postoperative gonadotropin-releasing hormone (GnRH) antagonist therapy, the tumor enlarged to 13 cm over nine months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.